Study Reveals Substantial Unmet Need in Psoriasis, Shows Strong Patient and Provider Preference for Highly Effective Oral Treatments With Favorable Safety Profile
October 28, 2025
October 28, 2025
RARITAN, New Jersey, Oct. 28 (TNSxrep) -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release on Oct. 27, 2025:
* * *
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
Findings highlight opportunity for shared decision-making to improve treatment plan . . .
* * *
New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
Findings highlight opportunity for shared decision-making to improve treatment plan . . .